Related references
Note: Only part of the references are listed.EV20-sss-vc/MMAF, an HER-3 targeting antibody-drug conjugate displays antitumor activity in liver cancer
Daniela D'Agostino et al.
ONCOLOGY REPORTS (2021)
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
Jim Middelburg et al.
CANCERS (2021)
Thirty Years of HER3: From Basic Biology to Therapeutic Interventions
Heidi M. Haikala et al.
CLINICAL CANCER RESEARCH (2021)
A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells
David J. DiLillo et al.
BLOOD ADVANCES (2021)
Bispecific antibodies
Ulrich Brinkmann et al.
SCIENCE (2021)
A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells
Nadine Aschmoneit et al.
SCIENTIFIC REPORTS (2021)
One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics
Wei Chen et al.
MABS (2021)
Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models
Feng Wang et al.
MABS (2020)
A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
Aerin Yoon et al.
BIOMOLECULES (2020)
Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies
Brian H. Santich et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach
Teilo H. Schaller et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody
Karin Staflin et al.
JCI INSIGHT (2020)
A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia
Priyanka Nair-Gupta et al.
BLOOD ADVANCES (2020)
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
Nathan D. Trinklein et al.
MABS (2019)
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
Lecia Sequist et al.
ONCOLOGIST (2019)
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer
Shigehiro Koganemaru et al.
MOLECULAR CANCER THERAPEUTICS (2019)
CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity
Ji Li et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study
Martin D. Forster et al.
EUROPEAN JOURNAL OF CANCER (2019)
T lymphocyte subsets in cancer immunity: Friends or foes
Dounia Chraa et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2019)
Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety
Diego Ellerman
METHODS (2019)
Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
William R. Strohl et al.
ANTIBODIES (2019)
Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig
Philip D. Bardwell et al.
PROTEIN & CELL (2018)
Clinical development of HER3-targeting monoclonal antibodies: Perils and progress
Wolfgang Jacob et al.
CANCER TREATMENT REVIEWS (2018)
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer
Andrew G. Hill et al.
CLINICAL CANCER RESEARCH (2018)
Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model
Danielle Mandikian et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1
Junpeng Qi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
The Neutrophil's Choice: Phagocytose vs Make Neutrophil Extracellular Traps
Angelo A. Manfredi et al.
FRONTIERS IN IMMUNOLOGY (2018)
Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
Bushra Husain et al.
BIODRUGS (2018)
Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
Sebastian Kobold et al.
FRONTIERS IN ONCOLOGY (2018)
Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3
Dionysos Slaga et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Regulatory mechanisms in T cell receptor signalling
Guillaume Gaud et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV
Lisa C. Schmitt et al.
MABS (2017)
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing
Ji Li et al.
CANCER CELL (2017)
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
Anja Seckinger et al.
CANCER CELL (2017)
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Marina Bacac et al.
CLINICAL CANCER RESEARCH (2016)
Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody
Sherri Dudal et al.
JOURNAL OF IMMUNOTHERAPY (2016)
Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
Maria-Elisabeth Goebeler et al.
LEUKEMIA & LYMPHOMA (2016)
Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds
Magdalena Malm et al.
MABS (2016)
Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
Vita Golubovskaya et al.
CANCERS (2016)
Origins of the cytolytic synapse
Maike de la Roche et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas
Simonetta M. Leto et al.
CLINICAL CANCER RESEARCH (2015)
Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
Julia Stieglmaier et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity
Ulrich Wuellner et al.
ANTIBODIES (2015)
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
Yang Xu et al.
BLOOD (2014)
Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands
Georges Vauquelin et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis
Alberto Ocana et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
T cell receptor signalling networks: branched, diversified and bounded
Rebecca J. Brownlie et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial (August, pg 1, 2012)
Christopher Horvath et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
Claudia Bluemel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy
Marcia R. Campbell et al.
CLINICAL CANCER RESEARCH (2010)
Mechanisms of resistance to HER family targeting antibodies
Tim J. Kruser et al.
EXPERIMENTAL CELL RESEARCH (2010)
Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion
Syd Johnson et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
The analysis of the functions of human B and T cells in humanized NOD/shi-scid/γcnull (NOG) mice (hu-HSC NOG mice)
Yohei Watanabe et al.
INTERNATIONAL IMMUNOLOGY (2009)
Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers
GP Adams et al.
CLINICAL CANCER RESEARCH (2006)
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
S Offner et al.
MOLECULAR IMMUNOLOGY (2006)
Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice
F Ishikawa et al.
BLOOD (2005)
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells
CA Klebanoff et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes
T Korn et al.
JOURNAL OF IMMUNOTHERAPY (2004)
Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction:: Manifestation of a dual activation threshold
M Faroudi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
